Beckman Coulter Diagnostics

A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory’s role in improving patient health for 90 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science and technology. Our diagnostic solutions are used in complex clinical testing and are found in hospitals and reference laboratories around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what’s now to what’s next. Beckman Coulter is part of Danaher Corporation and, headquartered in Brea, California, has more than 11,000 team members worldwide.

Approach to Healthcare:

Beckman Coulter Diagnostics is committed to advancing healthcare by delivering innovative diagnostic solutions that support earlier, more accurate clinical decision-making. Our approach centres on partnering with laboratories and clinicians to improve patient outcomes through reliable, high‑quality testing and efficient workflows. By combining scientific expertise, automation, and data-driven insights, we help healthcare systems optimise resources, enhance diagnostic confidence, and enable timely interventions. Across acute and routine care settings, our solutions support faster diagnosis, improved risk assessment, and better patient management, contributing to more effective, sustainable healthcare delivery worldwide.

Impact of Products/Services on Healthcare:

Our diagnostic solutions address the need for earlier insight and greater confidence in clinical decision‑making. In acute and infectious care, technologies such as Monocyte Distribution Width (MDW) and host‑response assays like MeMed help clinicians assess infection and sepsis risk sooner. By reducing diagnostic uncertainty and supporting timely intervention, our solutions help improve patient outcomes and optimise use of healthcare resources.

Innovation:

Recent innovations include the DxI 9000 high‑throughput immunoassay analyser, designed to support the needs of modern, high‑volume laboratories. Advances such as Monocyte Distribution Width (MDW) and host‑response technologies like MeMed provide new clinical insight into infection and sepsis, supporting earlier risk assessment, improved clinical confidence, and more informed decision‑making.

Future Direction:

Future focus is on advancing diagnostics that support earlier insight, greater clinical confidence, and improved efficiency across healthcare. This includes ongoing investment in innovative biomarkers, host‑response technologies, and scalable laboratory platforms to support acute care, including sepsis and infection pathways. By continuing to collaborate closely with healthcare partners, future developments aim to enable faster decision‑making, support sustainable laboratory services, and ultimately improve patient outcomes.